Efficacy of infliximab in acute severe ulcerative colitis: A single-centre experience

Table 2 Clinical characteristics and demographics of 44 patients with acute severe ulcerative colitis receiving infliximab, according to colectomy status after index admission and at last point of follow-up n (%)

	Colectomy status after index admission			Colectomy status at last point of follow-up
	Colectomy during index admission (n = 9)	Discharged colectomy-free (n = 35)	P value2	Colectomy during index admission or follow-up (n = 15)	Colectomy-free survival (n = 29)	P value2
Age at index admission1	45.6 ± 24.7	33.2 ± 12.1	0.18	42.2 ± 21.4	32.4 ± 11.3	0.11
Male	7 (77.8)	21 (60.0)	0.45	10 (66.7)	18 (62.1)	1.0
First presentation of UC	5 (55.6)	7 (20.0)	0.09	6 (40.0)	6 (20.7)	0.28
Disease extent	E1: 0 (0)	E1: 2 (5.7)		E1: 2 (13.3)	E1: 0 (0)
	E2: 3 (33.3)	E2: 10 (28.6)		E2: 3 (20.0)	E2: 10 (34.5)
	E3: 6 (66.7)	E3: 23 (65.7)	0.753	E3: 10 (66.7)	E3: 19 (65.5)	0.103
Current or previous smoker	4 (44.4)	14 (40.0)	1.0	6 (40.0)	12 (41.4)	1.0
Prescribed oral 5-ASA on admission	3 (33.3)	21 (60.0)	0.26	8 (53.3)	16 (55.2)	1.0
Prescribed thiopurine on admission	0 (0)	14 (40.0)	0.04	3 (20.0)	11 (37.9)	0.31
CRP (mg/L): day 01	163 ± 62.5	71 ± 76	0.002	111.0 ± 83.0	79.0 ± 80.6	0.23
CRP (mg/L): day1	96 ± 69	39 ± 41.5	0.04	65.3 ± 65.5	42.9 ± 44.3	0.25
Number of stools per day: day 01	13.3 ± 5.6	11.7 ± 5.9	0.46	13.0 ± 5.7	11.6 ± 5.9	0.44
Number of stools per day: day 31	8.7 ± 4.6	6.5 ± 3.3	0.21	7.7 ± 4.2	6.6 ± 3.3	0.39
Met Travis criteria at day 3	9 (100)	15 (42.9)	0.002	10 (66.7)	14 (48.3)	0.34
Received IFX on day 5 or sooner	1 (11.1)	11 (31.4)	0.41

¹Data are presented as mean ± SD;

²Independent samples t-test for continuous data and Fisher’s exact test for categorical data;

³χ² for trend. UC: Ulcerative colitis; 5-ASA: 5-aminosalicylate; CRP: C-reactive protein; IFX: Infliximab.